NASDAQ · ACAD
Healthcare · Biotechnology
$19.78
Up+$0.20 (+1.02%)
Updated Oct 12, 2026, 10:31 AM
SID Score
4.6/10
Composite research score
Smart Money
58/100
Neutral
Price performance · ACAD
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 9, 2026
ACAD closed at $19.78 after 20 trading sessions, down 28.13% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 9, 2026 | $19.60 | $20.05 | $19.58 | $19.78 | 1.47M |
| Oct 8, 2026 | $19.46 | $19.785 | $19.315 | $19.58 | 2.01M |
| Oct 7, 2026 | $19.60 | $19.7968 | $19.455 | $19.65 | 1.78M |
| Oct 6, 2026 | $20.16 | $20.36 | $19.67 | $19.74 | 1.67M |
| Oct 5, 2026 | $20.045 | $20.45 | $19.5662 | $20.11 | 3.15M |
| Oct 2, 2026 | $20.01 | $20.24 | $19.875 | $19.95 | 2.56M |
| Oct 1, 2026 | $19.95 | $20.19 | $19.59 | $19.89 | 2.73M |
| Sep 30, 2026 | $20.275 | $20.70 | $19.93 | $20.15 | 3.13M |
| Sep 29, 2026 | $20.605 | $20.605 | $20.06 | $20.22 | 2.52M |
| Sep 28, 2026 | $20.53 | $20.63 | $19.80 | $20.53 | 3.52M |
| Sep 25, 2026 | $22.21 | $22.21 | $20.61 | $20.68 | 3.36M |
| Sep 24, 2026 | $24.38 | $24.38 | $21.97 | $22.18 | 6.76M |
| Sep 23, 2026 | $26.41 | $26.51 | $24.93 | $25.43 | 1.31M |
| Sep 22, 2026 | $26.65 | $26.855 | $26.32 | $26.41 | 1.47M |
| Sep 21, 2026 | $27.43 | $27.43 | $26.34 | $26.395 | 1.35M |
| Sep 18, 2026 | $27.37 | $27.475 | $26.73 | $27.29 | 5.48M |
| Sep 17, 2026 | $27.78 | $28.06 | $27.29 | $27.45 | 1.31M |
| Sep 16, 2026 | $26.75 | $27.60 | $26.66 | $27.54 | 1.41M |
| Sep 15, 2026 | $27.51 | $27.51 | $26.64 | $26.76 | 1.11M |
| Sep 14, 2026 | $27.995 | $28.10 | $27.3817 | $27.52 | 1.63M |
The latest Smart Investors Daily articles mentioning ACAD.
Company
Market Activity
Research & News
ACAD research
Company profile and research snapshot.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 8, 2026 | RBC Capital | Outperform | — |
| Sep 25, 2026 | Deutsche Bank | Buy | — |
| Sep 25, 2026 | HC Wainwright & Co. | Buy | — |
| Sep 25, 2026 | Citizens | Market Outperform | — |
| Sep 25, 2026 | BMO Capital | Outperform | — |
No generated briefing is available yet.
Benzinga · Sep 11, 2026
On August 24, 2026, the United States District Court for the Southern District of California (the "Court") preliminarily approved the settlement ("Settlement") of the stockholder derivative action
Yahoo · Sep 3, 2026
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Yahoo · Aug 31, 2026
AcadeMedia (OM:ACAD) has drawn fresh attention after reporting its fourth quarter and full year results to June 30, 2026. The sales and net income figures indicate stronger operational performance across the education portfolio. The earnings release on 31 August appears to have reset expectations around AcadeMedia, with the share price up 3.47% on the day and 6.51% over the past week to SEK101.4. That builds on a 90 day share price return of 8.22% and a 1 year total shareholder return of...
ChartMill · Aug 31, 2026
ACADIA Pharmaceuticals (ACAD) passes the high growth momentum screen with strong technical and setup ratings, backed by solid earnings growth, upward revisions, and a bullish chart.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ACAD.
